Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Investors
Analyst coverage
| FIRM | ANALYST |
| Morgan Stanley | Karl D Bradshaw, PhD |
| Bank Sal. Oppenheim | Carri Duncan, PhD |
| Bank Vontobel AG | Andrew Weiss |
| Kepler Equities | Florian Gaiser, PhD CFA |
| Helvea SA | Olav Zilian, M.D. Ph.D |
| Bank am Bellevue | Bob Pooler |
| Piper Jaffray | Sam Fazeli; Michael Aitkenhead |
| Jefferies | Peter Welford, Philippa Gardner,Tara Shivarattan |